Kinnate Biopharma Inc logo

KNTE

Kinnate Biopharma Inc

$14.3

Earnings Summary

Revenue
$0Mn
Net Profits
$-26.9Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Kinnate Biopharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Kinnate Biopharma Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Kinnate Biopharma Inc’s net profit fell -96.26% since last year same period to $-26.9Mn in the Q1 2022. On a quarterly growth basis, Kinnate Biopharma Inc has generated 38.32% jump in its net profits since last 3-months.

Net Profit Margins:

Kinnate Biopharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Kinnate Biopharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kinnate Biopharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.64
EPS Estimate Current Year
-0.64

Highlights

EPS Estimate Current Quarter:

Kinnate Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a -4.92% fall from last quarter’s estimates.

EPS Estimate Current Year:

Kinnate Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.64.

Key Ratios

Key ratios of the Kinnate Biopharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.61
Return on Assets (ROA)
-0.18
Return on Equity (ROE)
-0.3
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Kinnate Biopharma Inc’s earning per share (EPS) fell -52.5% since last year same period to -0.61 in the Q1 2022. This indicates that the Kinnate Biopharma Inc has generated -52.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kinnate Biopharma Inc’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kinnate Biopharma Inc’s return on equity (ROE) stands at -0.3.

Dividend Per Share (DPS):

Kinnate Biopharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.61
-0.61
0%

Company Information

Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.

Organisation
Kinnate Biopharma Inc
Headquarters
103 Montgomery Street, San Francisco, CA, United States, 94129
Employees
31